1. Academic Validation
  2. Novel 6β-acylaminomorphinans with analgesic activity

Novel 6β-acylaminomorphinans with analgesic activity

  • Eur J Med Chem. 2013 Nov:69:786-9. doi: 10.1016/j.ejmech.2013.09.031.
András Váradi 1 Sándor Hosztafi Valerie Le Rouzic Gergő Tóth Ákos Urai Béla Noszál Gavril W Pasternak Steven G Grinnell Susruta Majumdar
Affiliations

Affiliation

  • 1 Department of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9, Budapest H-1092, Hungary; Molecular Pharmacology and Chemistry Program and Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA. Electronic address: varadi.andras@pharma.semmelweis-univ.hu.
Abstract

Aminomorphinans are a relatively young class of opioid drugs among which substances of high in vitro efficacy and favorable in vivo action are found. We report the synthesis and pharmacological evaluation of novel 6β-acylaminomorphinans. 6β-Morphinamine and 6β-codeinamine were stereoselectively synthesized by Mitsunobu reaction. The aminomorphinans were subsequently acylated with diversely substituted cinnamic acids. In vitro binding studies on cinnamoyl morphinamines showed moderate affinity for all opiate receptors with some selectivity for mu opioid receptors, while cinnamoyl codeinamines only showed affinity for mu opioid receptors. In vivo analgesia studies showed significant analgesic activity of 6β-cinnamoylmorphinamine mediated by mu and delta receptors. The lead compound was found to be roughly equipotent to morphine (ED₅₀ 3.13 ± 1.09 mg/kg) but devoid of the dangerous side-effect respiratory depression, a major issue associated with traditional opioid therapy.

Keywords

Aminomorphinan; Analgesia; Cinnamoyl morphinamine; MOR/DOR agonist; Opioid; Respiratory depression.

Figures